Harte Hanks (HHS) Cash & Equivalents (2010 - 2026)

Harte Hanks (HHS) has 17 years of Cash & Equivalents data on file, last reported at $4.5 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $4.5 million, down 49.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.5 million (down 49.48% YoY), and the FY2025 annual result was $5.6 million, down 43.76% from the prior year.
• Cash & Equivalents fell to $4.5 million in Q1 2026 per HHS's latest filing, from $5.6 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $18.9 million in Q4 2023 and troughed at $4.5 million in Q1 2026.
• A 5-year average of $9.7 million and a median of $9.9 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2022 and 2023: Cash & Equivalents plunged 63.57% in 2022, then surged 92.38% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $10.4 million in 2022, then jumped by 82.01% to $18.9 million in 2023, then plunged by 47.34% to $9.9 million in 2024, then sank by 43.76% to $5.6 million in 2025, then retreated by 18.78% to $4.5 million in 2026.
• Business Quant data shows HHS's Cash & Equivalents at $4.5 million in Q1 2026, $5.6 million in Q4 2025, and $6.5 million in Q3 2025.